259 results on '"Hattinger, Claudia"'
Search Results
2. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma
3. Biology of Osteosarcomas
4. Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.
5. Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines
6. Biology of Osteosarcomas
7. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma
8. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma
9. Data from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
10. Data from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
11. Supplementary materials from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
12. Supplementary Figure S7 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
13. Supplementary Table 3 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
14. Supplementary Table 1 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
15. Supplementary Table 6 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
16. Supplementary Table 5 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
17. Supplementary Figures 1 - 11 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
18. Supplementary Table 2 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
19. Supplementary Table 4 from A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
20. Supplementary Figure 1 from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
21. Supplementary Table 3 from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
22. Supplementary Table 2 from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
23. Supplementary Figure 2 from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
24. Supplementary Table 1 from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
25. Data from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
26. Supplementary Figure and Table Legends from Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma
27. Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
28. Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
29. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types
30. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
31. Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
32. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy
33. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
34. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
35. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
36. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma
37. Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
38. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma
39. Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
40. Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
41. Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
42. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
43. The use of laryngeal tube by nurses in out-of-hospital emergencies: Preliminary experience
44. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts
45. An update on emerging drugs in osteosarcoma: towards tailored therapies?
46. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
47. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma
48. Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?
49. Abstract 2077: Genome-wide association study identifies theGLDC/IL33locus associated with survival of osteosarcoma patients
50. Genome-wide association study identifies theGLDC/IL33locus associated with survival of osteosarcoma patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.